The COVID-19 pandemic showed the world how vulnerable—and resilient—the supply chain is. Specifically, pharmaceutical manufacturers dealt with employee shortages, closed borders, stock outages, limited product visibility, and more.
The COVID-19 pandemic showed the world how vulnerable—and resilient—the supply chain is. Specifically, pharmaceutical manufacturers dealt with employee shortages, closed borders, stock outages, limited product visibility, and more. The rapid development and deployment of the much-needed COVID-19 vaccines added another layer of complexity that the industry had never experienced. It became obvious that collaboration and automation were necessary to overcome these issues. And beyond the added challenges of the vaccine distribution, normal excursions are still a threat to patient safety. They can lead to time-consuming and costly investigations that delay getting necessary medication to consumers. Real-time visibility, process automation, and a comprehensive control tower can prevent excursions, reduced time spent on quality issues, and help pinpoint supply chain vulnerabilities.
Pharmaceutical manufacturers and their logistics partners have specific business rules and policies that they abide by to keep products safe throughout the supply and distribution chain. These can relate to various aspects of product safety and quality conditions including, temperature excursions, improper locations, logistics challenges, pallets being split, light events, suspected theft or tampering, and more. When pharmaceutical manufacturers experience one of these incidents, the entire batch or pallet will have to be investigated and possibly destroyed. Quality assurance (QA) teams spend hundreds of hours every year reviewing and examining quality incidents. Many of those hours could be spent on other functions, like process improvement, if quality condition notifications were automated and addressed as they occur.
Real-time supply chain monitoring technology is one tool that QA professionals can utilize to minimize investigation time via alerts about possible incidents as they are happening. Internet of Things (IoT) data loggers and cloud computing are ways to see what is happening to products—in real-time. Moving beyond those two tools, automating processes and workflows can dramatically decrease the time spent reviewing escalations because they allow for the immediate release of pharmaceuticals if no excursions have occurred. They also provide the opportunity to prevent excursions with automatic alerts notifying the appropriate parties to look into the issue before affecting product quality conditions.
Within the supply chain, multiple stakeholders and hand-off points leave products vulnerable to safety and quality issues. And each party is likely to have its own business system, such as enterprise resource planning, warehouse management, or quality management systems. These platforms all give detailed and useful data; however, if they are not automatically linked together into a control tower, organizations are likely missing out on key issues throughout the supply chain. This is especially true when using passive data loggers that only give historical information.
Since the pandemic began, we have seen the pharmaceutical distribution model get an overhaul in just a few months, mainly through the integration of multiple business platforms, increased data sharing, and technology-enabled responsiveness, all resulting in an enhanced pharmaceutical control tower. When organizations have an automated and comprehensive control tower, they are no longer drowning in data. Parties receive reports that combine information from different systems, people, and organizations into useful data that shows them what is happening, what is likely to happen, and how to prevent issues in the future. Notifications about product quality conditions help stakeholders understand the decisions to be made and what the next steps are so that the shipment is not delayed or damaged. All of this saves time, improves product quality, and safely gets the pharmaceuticals to patients.
Collaboration has been a hallmark of the pharmaceutical supply chain during the COVID-19 pandemic. Companies that might have formerly considered each other competitors now work side by side to manage and minimize the global crisis. Technology has been a critical source of increased collaboration with all pharmaceutical supply chain stakeholders. Real-time monitoring with predictive analytics builds a cohesive supply chain where parties understand how to make the best decision with the information at hand. Control tower technology is also the most efficient way to automate processes and allow companies to execute planning and strategy in a whole new way. It connects the digital and physical supply chain and links stakeholders across the value chain.
The real-time monitoring technology used in the COVID-19 vaccine distribution empowers supply chain stakeholders to work together and prevent quality issues from happening. At the same time, keeping data over time shows what could happen in the future based on predictive information. An example of this would be seeing that certain products going through a particular airport always have an issue, like going outside approved temperature ranges. Having this information can spur an investigation or offer opportunities for additional training on product handling. Over time, this data will continue to grow, showing more ways to improve processes that prevent waste and stock outages. It can help pharmaceutical companies determine the most effective packaging type or which carriers are best suited for their business model.
When organizations across the supply chain work together and share data, amazing things can happen, which we have all witnessed through the global crisis. The pharmaceutical supply chain has been reinvigorated and made stronger through close collaboration. And technology is fueling the transformation by improving delivery time and product safety through automatic releases, integrating multiple systems into one control tower, and increasing collaboration throughout the entire supply chain.
Ada Palmadottir is Business Development Director at Controlant. With more than 20 years of experience in pharmacy, management, and technology, Ada has extensive international experience in sales, operations, and marketing, specifically in the areas of product, vertical alliance sales, and partnerships related to pharmaceutical products. She is a licensed and experienced pharmacist and earned a Master of Pharmacy from the University of Iceland and a Master of Business Administration from the Norwegian School of Management in Oslo. Ada has been working with Controlant for more than ten years.
The clinical trial market is in a state of flux; innovative therapies, working practices and startups are creating a landscape of constant churn. To navigate it, supply chain optimisation will be essential.
New technology is sometimes sluggish to penetrate the pharmaceutical industry. With an era of digital transformation promising to optimize pharmaceutical supply chains, how are companies learning to embrace the change?